GlassScriptPhysician profile
Katherine L Shepherd
NPI 1528327442
$2,808.13
in general payments reported to CMS, 2019-2025
30 companies · $663 in 2025
The $663 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $115 · 2022: $413 · 2023: $433 · 2024: $585 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,681.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $495.62 | 2022-2025 | Nexplanon, Nuvaring |
| Hologic Sales and Service, LLC | $310.04 | 2020-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Abbvie INC. | $232.40 | 2019-2025 | Orilissa, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $227.43 | 2023-2025 | |
| Exeltis, USA INC. | $196.57 | 2019-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $175.10 | 2019-2024 | |
| Pfizer INC. | $162.58 | 2019-2025 | |
| Astellas Pharma US INC | $149.03 | 2024-2025 | Veozah, Vesicare |
| Sumitomo Pharma America, INC. | $98.31 | 2025 | Myfembree |
| Roche Diagnostics Corporation | $79.42 | 2019 | |
| Lupin INC. | $78.88 | 2019 | |
| Merck Sharp & Dohme LLC | $73.42 | 2019-2020 | |
| Shield Therapeutics INC | $66.72 | 2024-2025 | |
| Amgen INC. | $57.43 | 2019-2024 | Prolia, Evenity |
| Sage Therapeutics, LLC | $55.32 | 2019-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $40.70 | 2019 | |
| Minerva Surgical, INC | $36.78 | 2023 | |
| Therapeuticsmd, INC. | $35.78 | 2019 | |
| Millicent US INC | $32.65 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Alexion Pharmaceuticals, INC. | $27.42 | 2023 | Ultomiris |
| Innovation Technologies INC | $24.84 | 2023 | Irrisept |
| Daiichi Sankyo INC. | $24.24 | 2019 | |
| Boston Scientific Corporation | $21.03 | 2019 | |
| Averitas Pharma INC. | $20.03 | 2024 | Qutenza |
| Agile Therapeutics, INC. | $19.76 | 2024 | Twirla |
| Allergan, INC. | $17.18 | 2019 | |
| Avion Pharmaceuticals | $14.67 | 2019 | |
| Mallinckrodt Enterprises LLC | $11.71 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.62 | 2020 | |
| Mission Pharmacal Company | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.